ArticleJournal of cosmetic dermatology2025
Injectable Aesthetic Treatments for Improving Facial Skin Quality in Transgender Patients With or Without Gender-Affirming Hormone Therapy.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbiome-Directed Bioactive Strategies in Skin Aging: Mechanistic Insights and Precision Nanocarrier Delivery Approaches.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpecialized medical care for transgender patients during the transition process can substantially improve mental and physical health for this population, due to the multitude of changes they may experience in both areas. Minimally invasive aesthetic procedures (MIPs) on the face can promote the anatomical changes and skin quality improvements necessary for gender affirmation, increasing gender congruence and, consequently, improving patients' quality of life. Given that gender-affirming hormone therapy (GAHT) impacts skin quality, MIPs may offer valuable complementary benefits during the transition process.
objectiveHere we describe a novel treatment plan to improve skin quality in transgender patients who are or are not undergoing GAHT.
methodThe combination of incobotulinumtoxinA (Xeomin; Merz Pharmaceuticals GmbH, Frankfurt, Germany), calcium hydroxylapatite-carboxymethylcellulose (Radiesse; Merz North America Inc., Franksville, WI, USA), and Cohesive Polydensified Matrix hyaluronic acid with glycerol (CMP-HA20G, Belotero Revive; Anteis S.A., Plan-les-Ouates, Switzerland, a company of the Merz Aesthetics group) should be administered in a single session to improve skin quality. Photographs were taken at baseline and follow-up to assist with 3-dimensional reconstructions for evaluation of skin quality according to the four emergent perceptual categories (EPCs) defining skin quality. OUTCOMES: EPC monitoring may help to guide MIP treatments, support future evaluation of treatment efficiency, and assist in delivering personalized gender-affirming care.
conclusionThis new treatment plan for skin quality improvement offers gender-affirming care to the transgender community, based on clinical expertise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.